CN100450483C - 含有钙阻滞剂的稳定药物组合物 - Google Patents
含有钙阻滞剂的稳定药物组合物 Download PDFInfo
- Publication number
- CN100450483C CN100450483C CNB018109438A CN01810943A CN100450483C CN 100450483 C CN100450483 C CN 100450483C CN B018109438 A CNB018109438 A CN B018109438A CN 01810943 A CN01810943 A CN 01810943A CN 100450483 C CN100450483 C CN 100450483C
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- methyl
- magnesium
- azetidinyl
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 44
- 229940127291 Calcium channel antagonist Drugs 0.000 title abstract 3
- 239000000480 calcium channel blocker Substances 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 claims abstract description 54
- 239000007864 aqueous solution Substances 0.000 claims abstract description 14
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 14
- 150000003839 salts Chemical class 0.000 claims abstract description 13
- 239000006185 dispersion Substances 0.000 claims abstract description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 8
- -1 1-benzyl-3-azetidinyl Chemical group 0.000 claims description 104
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 25
- 239000004305 biphenyl Substances 0.000 claims description 23
- 230000001126 calcilytic effect Effects 0.000 claims description 23
- 229910052731 fluorine Inorganic materials 0.000 claims description 19
- 239000011737 fluorine Substances 0.000 claims description 18
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 15
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 14
- ZKFQEACEUNWPMT-UHFFFAOYSA-N Azelnidipine Chemical compound CC(C)OC(=O)C1=C(C)NC(N)=C(C(=O)OC2CN(C2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZKFQEACEUNWPMT-UHFFFAOYSA-N 0.000 claims description 13
- 229950004646 azelnidipine Drugs 0.000 claims description 13
- JAUGGEIKQIHSMF-UHFFFAOYSA-N dialuminum;dimagnesium;dioxido(oxo)silane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O JAUGGEIKQIHSMF-UHFFFAOYSA-N 0.000 claims description 13
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 7
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 7
- MFYLRNKOXORIPK-UHFFFAOYSA-N (3-nitrophenyl)-phenylmethanone Chemical compound [O-][N+](=O)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 MFYLRNKOXORIPK-UHFFFAOYSA-N 0.000 claims description 6
- HZVVJJIYJKGMFL-UHFFFAOYSA-N almasilate Chemical compound O.[Mg+2].[Al+3].[Al+3].O[Si](O)=O.O[Si](O)=O HZVVJJIYJKGMFL-UHFFFAOYSA-N 0.000 claims description 6
- 235000012241 calcium silicate Nutrition 0.000 claims description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 5
- 239000001301 oxygen Substances 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 229910052910 alkali metal silicate Inorganic materials 0.000 claims description 4
- 229910052915 alkaline earth metal silicate Inorganic materials 0.000 claims description 4
- UJHSIDUUJPTLDY-UHFFFAOYSA-N (2-nitrophenyl)-phenylmethanone Chemical compound [O-][N+](=O)C1=CC=CC=C1C(=O)C1=CC=CC=C1 UJHSIDUUJPTLDY-UHFFFAOYSA-N 0.000 claims description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 3
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical group [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 claims description 3
- 239000000391 magnesium silicate Substances 0.000 claims description 3
- 229910052919 magnesium silicate Inorganic materials 0.000 claims description 3
- 235000019792 magnesium silicate Nutrition 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract description 5
- 238000003860 storage Methods 0.000 abstract description 5
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 3
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 239000002585 base Substances 0.000 description 19
- 238000002360 preparation method Methods 0.000 description 18
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 17
- 150000001875 compounds Chemical class 0.000 description 15
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 9
- 238000001035 drying Methods 0.000 description 9
- 238000009775 high-speed stirring Methods 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 229920002678 cellulose Polymers 0.000 description 8
- 239000001913 cellulose Substances 0.000 description 8
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 7
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 6
- 229960002992 barnidipine Drugs 0.000 description 6
- VXMOONUMYLCFJD-DHLKQENFSA-N barnidipine Chemical compound C1([C@@H]2C(=C(C)NC(C)=C2C(=O)OC)C(=O)O[C@@H]2CN(CC=3C=CC=CC=3)CC2)=CC=CC([N+]([O-])=O)=C1 VXMOONUMYLCFJD-DHLKQENFSA-N 0.000 description 6
- 229960004916 benidipine Drugs 0.000 description 6
- QZVNQOLPLYWLHQ-ZEQKJWHPSA-N benidipine Chemical compound C1([C@H]2C(=C(C)NC(C)=C2C(=O)OC)C(=O)O[C@H]2CN(CC=3C=CC=CC=3)CCC2)=CC=CC([N+]([O-])=O)=C1 QZVNQOLPLYWLHQ-ZEQKJWHPSA-N 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 6
- 239000004744 fabric Substances 0.000 description 6
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 6
- 238000002372 labelling Methods 0.000 description 6
- 235000019359 magnesium stearate Nutrition 0.000 description 6
- 229960003963 manidipine Drugs 0.000 description 6
- ANEBWFXPVPTEET-UHFFFAOYSA-N manidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ANEBWFXPVPTEET-UHFFFAOYSA-N 0.000 description 6
- 235000010355 mannitol Nutrition 0.000 description 6
- 229960001783 nicardipine Drugs 0.000 description 6
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 6
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 6
- 229920000053 polysorbate 80 Polymers 0.000 description 6
- 229940068968 polysorbate 80 Drugs 0.000 description 6
- 238000010298 pulverizing process Methods 0.000 description 6
- 235000017550 sodium carbonate Nutrition 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- PVHUJELLJLJGLN-INIZCTEOSA-N (S)-nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-INIZCTEOSA-N 0.000 description 5
- XTFPDGZNWTZCMF-DHZHZOJOSA-N 3-o-methyl 5-o-[(e)-3-phenylprop-2-enyl] 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC\C=C\C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 XTFPDGZNWTZCMF-DHZHZOJOSA-N 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 5
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 5
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 5
- 229960000528 amlodipine Drugs 0.000 description 5
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 5
- 239000011230 binding agent Substances 0.000 description 5
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 5
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 5
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 5
- VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 description 5
- 229960000227 nisoldipine Drugs 0.000 description 5
- 229960005425 nitrendipine Drugs 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 229950004891 pranidipine Drugs 0.000 description 5
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 4
- 239000005711 Benzoic acid Substances 0.000 description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 4
- KJEBULYHNRNJTE-DHZHZOJOSA-N Cinalong Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC\C=C\C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 KJEBULYHNRNJTE-DHZHZOJOSA-N 0.000 description 4
- WTOVRSWDBLIFHU-UHFFFAOYSA-N Lemildipine Chemical compound COC(=O)C1=C(C)NC(COC(N)=O)=C(C(=O)OC(C)C)C1C1=CC=CC(Cl)=C1Cl WTOVRSWDBLIFHU-UHFFFAOYSA-N 0.000 description 4
- FAIIFDPAEUKBEP-UHFFFAOYSA-N Nilvadipine Chemical compound COC(=O)C1=C(C#N)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC([N+]([O-])=O)=C1 FAIIFDPAEUKBEP-UHFFFAOYSA-N 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 229910052783 alkali metal Inorganic materials 0.000 description 4
- 235000010233 benzoic acid Nutrition 0.000 description 4
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical class [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 4
- 229960003020 cilnidipine Drugs 0.000 description 4
- 229960003580 felodipine Drugs 0.000 description 4
- 229950001530 lemildipine Drugs 0.000 description 4
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 4
- 229960001597 nifedipine Drugs 0.000 description 4
- 229960005366 nilvadipine Drugs 0.000 description 4
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 4
- 150000004760 silicates Chemical class 0.000 description 4
- NSVFSAJIGAJDMR-UHFFFAOYSA-N 2-[benzyl(phenyl)amino]ethyl 5-(5,5-dimethyl-2-oxido-1,3,2-dioxaphosphinan-2-yl)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylate Chemical compound CC=1NC(C)=C(C(=O)OCCN(CC=2C=CC=CC=2)C=2C=CC=CC=2)C(C=2C=C(C=CC=2)[N+]([O-])=O)C=1P1(=O)OCC(C)(C)CO1 NSVFSAJIGAJDMR-UHFFFAOYSA-N 0.000 description 3
- ZGRIPYHIFXGCHR-UHFFFAOYSA-N 3-o-[2-[(4-fluorophenyl)methyl-methylamino]ethyl] 5-o-propan-2-yl 4-(1,3-benzodioxol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound C=1C=CC=2OCOC=2C=1C1C(C(=O)OC(C)C)=C(C)NC(C)=C1C(=O)OCCN(C)CC1=CC=C(F)C=C1 ZGRIPYHIFXGCHR-UHFFFAOYSA-N 0.000 description 3
- GGVUNNUOJDGCBK-UHFFFAOYSA-N 3-o-methyl 5-o-(oxolan-2-ylmethyl) 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC2OCCC2)C1C1=CC=CC=C1[N+]([O-])=O GGVUNNUOJDGCBK-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 3
- NCUCGYYHUFIYNU-UHFFFAOYSA-N Aranidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)=O)C1C1=CC=CC=C1[N+]([O-])=O NCUCGYYHUFIYNU-UHFFFAOYSA-N 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- 241001597008 Nomeidae Species 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 229950007556 aranidipine Drugs 0.000 description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 229950003102 efonidipine Drugs 0.000 description 3
- 229950010020 elgodipine Drugs 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 229950005851 furnidipine Drugs 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 229910052710 silicon Inorganic materials 0.000 description 3
- 239000010703 silicon Substances 0.000 description 3
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 3
- 239000004299 sodium benzoate Substances 0.000 description 3
- 235000010234 sodium benzoate Nutrition 0.000 description 3
- 230000000087 stabilizing effect Effects 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 3
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 2
- XPDWGBQVDMORPB-UHFFFAOYSA-N Fluoroform Chemical compound FC(F)F XPDWGBQVDMORPB-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical class OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 229910000287 alkaline earth metal oxide Inorganic materials 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 description 2
- 239000000292 calcium oxide Substances 0.000 description 2
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 235000013539 calcium stearate Nutrition 0.000 description 2
- 239000008116 calcium stearate Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 150000007942 carboxylates Chemical class 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 2
- 229940038472 dicalcium phosphate Drugs 0.000 description 2
- 229940117389 dichlorobenzene Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 2
- 239000001095 magnesium carbonate Substances 0.000 description 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 2
- 239000000395 magnesium oxide Substances 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 235000019426 modified starch Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical class CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- ZLXJGAJVOVWNFB-UHFFFAOYSA-M C(C)C(COP(=O)(OCC(CCCC)CC)[O-])CCCC.[Ba+] Chemical compound C(C)C(COP(=O)(OCC(CCCC)CC)[O-])CCCC.[Ba+] ZLXJGAJVOVWNFB-UHFFFAOYSA-M 0.000 description 1
- DACCGEAJIAWULJ-UHFFFAOYSA-M C(C)C(COP(=O)(OCC(CCCC)CC)[O-])CCCC.[Mg+] Chemical compound C(C)C(COP(=O)(OCC(CCCC)CC)[O-])CCCC.[Mg+] DACCGEAJIAWULJ-UHFFFAOYSA-M 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000790917 Dioxys <bee> Species 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical class OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004111 Potassium silicate Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000004115 Sodium Silicate Substances 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- NZJZJHQFVDOVMT-UHFFFAOYSA-N [O-2].[O-2].[O-2].[Al+3].[Al+3].O[Si](O)(O)O Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3].O[Si](O)(O)O NZJZJHQFVDOVMT-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 150000001399 aluminium compounds Chemical class 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229910000323 aluminium silicate Inorganic materials 0.000 description 1
- PZZYQPZGQPZBDN-UHFFFAOYSA-N aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- 229910001863 barium hydroxide Inorganic materials 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- XIWFQDBQMCDYJT-UHFFFAOYSA-M benzyl-dimethyl-tridecylazanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 XIWFQDBQMCDYJT-UHFFFAOYSA-M 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical class [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 239000007766 cera flava Substances 0.000 description 1
- 150000003841 chloride salts Chemical class 0.000 description 1
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229930003836 cresol Natural products 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229950007655 esilate Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical class OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
- 229910052808 lithium carbonate Inorganic materials 0.000 description 1
- HQRPHMAXFVUBJX-UHFFFAOYSA-M lithium;hydrogen carbonate Chemical compound [Li+].OC([O-])=O HQRPHMAXFVUBJX-UHFFFAOYSA-M 0.000 description 1
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium;hydroxide;hydrate Chemical compound [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 150000002681 magnesium compounds Chemical class 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 239000008342 pharmaceutical dispersion Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 235000019353 potassium silicate Nutrition 0.000 description 1
- 229910052913 potassium silicate Inorganic materials 0.000 description 1
- NNHHDJVEYQHLHG-UHFFFAOYSA-N potassium silicate Chemical compound [K+].[K+].[O-][Si]([O-])=O NNHHDJVEYQHLHG-UHFFFAOYSA-N 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical class CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000004290 sodium methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010268 sodium methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004404 sodium propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010230 sodium propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229910052911 sodium silicate Inorganic materials 0.000 description 1
- NTHWMYGWWRZVTN-UHFFFAOYSA-N sodium silicate Chemical compound [Na+].[Na+].[O-][Si]([O-])=O NTHWMYGWWRZVTN-UHFFFAOYSA-N 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229940084106 spermaceti Drugs 0.000 description 1
- 239000012177 spermaceti Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 229950004288 tosilate Drugs 0.000 description 1
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 1
- 235000019798 tripotassium phosphate Nutrition 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
- C07F9/657163—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom
- C07F9/657181—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom the ring phosphorus atom and, at least, one ring oxygen atom being part of a (thio)phosphonic acid derivative
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
本发明提供一种包含下式的钙阻滞剂或其药理学上可接受的盐、以及药理学上可接受的碱性介质的药物组合物,所述碱性介质的加入量使该含钙阻滞剂的药物组合物的水溶液或分散液至少为pH8。式中R1表示任选取代的C1-C4烷基、氨基或氰基;R2表示任选取代的C1-C4烷基、被取代的C3-C4链烯基或被取代的4-6元环状氨基;R3表示被取代的苯基;R4表示任选取代的C1-C4烷氧羰基、1,3,2-膦杂环己烷-2-基或5,5-二甲基-1,3,2-膦杂环己烷-2-基;R5表示C1-C4烷基。
Description
技术领域
本发明涉及含有钙阻滞剂的稳定药物组合物。
技术背景
钙阻滞剂是广为人知的降压药物,可制造各种制剂,市场上也有出售(例如美国专利第3,485,847号、美国专利第3,985,758号、美国专利第4,572,909号等)。
但是过去的制剂在储存稳定性等稳定性方面不一定能满足要求,需要有具备优良储存稳定性的药物组合物。
本发明者们对含有钙阻滞剂的药物组合物进行了长期深入的研究,结果通过在钙阻滞剂中混入药理学上可接受的碱性介质,发现了在储存稳定性等方面具有优良稳定性的药物组合物,从而完成了本发明。
本发明提供含有钙阻滞剂的稳定药物组合物。
发明的公开
本发明为含有钙阻滞剂的药物组合物,该组合物包含具有下述通式的钙阻滞剂或其药理学上可接受的盐、以及可使药物组合物的水溶液或分散液至少为pH8的药理学上可接受的碱性介质,
[式中R1表示可被氨基甲酰氧基或2-氨基乙氧基取代的C1-C4烷基、氨基或氰基,
R2表示可被乙酰基、N-甲基-N-(可被氟取代的苯基甲基)氨基、N-(可被氟取代的苯基)-N-(可被氟取代的苯基甲基)氨基、2-四氢呋喃基或4-[可被氟取代的苯基甲基或二(可被氟取代的苯基)甲基]-1-哌嗪基取代的C1-C4烷基,被可被氟取代的苯基取代的C3-C4链烯基或者其氮原子被可被氟取代的苯基甲基或者二(可被氟取代的苯基)甲基取代的4-6元环状氨基,
R3表示具有选自卤素、硝基和1,2-亚甲基二氧基的1-2个取代基的苯基,
R4表示可被甲氧基取代的C1-C4烷氧羰基、1,3,2-膦杂环己烷(phosphorinan)-2-基或5,5-二甲基-1,3,2-膦杂环己烷-2-基,
R5表示C1-C4烷基]。
在上述通式(I)中,
R1的可被氨基甲酰氧基或2-氨基乙氧基取代的C1-C4烷基的C1-C4烷基部分,R2的可被乙酰基、N-甲基-N-(可被氟取代的苯基甲基)氨基、N-(可被氟取代的苯基)-N-(可被氟取代的苯基甲基)氨基、2-四氢呋喃基或4-[可被氟取代的苯基甲基或二(可被氟取代的苯基)甲基]-1-哌嗪基取代的C1-C4烷基的C1-C4烷基部分,R4的可被甲氧基取代的C1-C4烷氧羰基的C1-C4烷基部分以及R5的C1-C4烷基可以是例如甲基、乙基、丙基、异丙基、丁基、异丁基、仲丁基或叔丁基;R1和R5优选为甲基或乙基,更优选为甲基;R2优选为甲基、乙基、异丙基或异丁基;R4优选为甲基、乙基或异丙基。
R2的被可被氟取代的苯基取代的C3-C4链烯基可以是例如3-苯基-2-丙烯基、3-(4-氟代苯基)-2-丙烯基、4-苯基-3-丁烯基或2-甲基-3-苯基-2-丙烯基,优选3-苯基-2-丙烯基。
R2的其氮原子被可被氟取代的苯基甲基或者二(可被氟取代的苯基)甲基取代的4-6元环状氨基为例如1-苄基-3-氮杂环丁烷基、1-二苯基甲基-3-氮杂环丁烷基、1-(二-4-氟代苯基甲基)-3-氮杂环丁烷基、1-苄基-3-吡咯烷基、1-(4-氟代苯基甲基)-3-吡咯烷基、1-二苯基甲基-3-吡咯烷基、1-苄基-3-哌啶基、1-(4-氟代苯基甲基)-3-哌啶基或1-二苯基甲基-3-哌啶基,优选1-苄基-3-氮杂环丁烷基、1-二苯基甲基-3-氮杂环丁烷基、1-苄基-3-吡咯烷基或1-苄基-3-哌啶基,更优选1-二苯基甲基-3-氮杂环丁烷基。
R3中所含的卤素为例如氟、氯、溴或碘,优选氟或氯,更优选氯。
R1优选为甲基、氨基甲酰氧基甲基、2-氨基乙氧基甲基、乙基、2-氨基甲酰氧基乙基、2-(2-氨基乙氧基)乙基、氨基或氰基,更优选为甲基、氨基甲酰氧基甲基、2-氨基乙氧基甲基、氨基或氰基,更加优选甲基或氨基,最优选为氨基。
R2优选为甲基、乙酰基甲基、2-四氢呋喃基甲基、乙基、2-乙酰基乙基、2-(N-甲基-N-苄基氨基)乙基、2-[N-甲基-N-(4-氟代苯基甲基)氨基]乙基、2-(N-苯基-N-苄基氨基)乙基、2-[N-(4-氟代苯基)-N-苄基氨基]乙基、2-[N-(4-氟代苯基)-N-(4-氟代苯基甲基)氨基]乙基、2-(4-苄基-1-哌嗪基)乙基、2-[4-(4-氟代苯基甲基)-1-哌嗪基]乙基、2-(4-二苯基甲基-1-哌嗪基)乙基、2-[4-(二-4-氟代苯基甲基)-1-哌嗪基]乙基、异丙基、异丁基、3-苯基-2-丙烯基、3-(4-氟代苯基)-2-丙烯基、4-苯基-3-丁烯基、2-甲基-3-苯基-2-丙烯基、1-苄基-3-氮杂环丁烷基、1-二苯基甲基-3-氮杂环丁烷基、1-(二-4-氟代苯基甲基)-3-氮杂环丁烷基、1-二苯基甲基-3-氮杂环丁烷基、1-(二-4-氟代苯基甲基)-3-氮杂环丁烷基、1-苄基-3-吡咯烷基、1-(4-氟代苯基甲基)-3-吡咯烷基、1-二苯基甲基-3-吡咯烷基、1-苄基-3-哌啶基、1-(4-氟代苯基甲基)-3-哌啶基或1-二苯基甲基-3-哌啶基,更优选为甲基、乙酰基甲基、2-四氢呋喃基甲基、乙基、2-(N-甲基-N-苄基氨基)乙基、2-[N-甲基-N-(4-氟代苯基甲基)氨基]乙基、2-(N-苯基-N-苄基氨基)乙基、2-(4-二苯基甲基-1-哌嗪基)乙基、异丙基、异丁基、3-苯基-2-丙烯基、1-苄基-3-氮杂环丁烷基、1-二苯基甲基-3-氮杂环丁烷基、1-(二-4-氟代苯基甲基)-3-氮杂环丁烷基、1-苄基-3-吡咯烷基或1-苄基-3-哌啶基,更加优选为甲基、乙基、2-(4-二苯基甲基-1-哌嗪基)乙基、异丁基、3-苯基-2-丙烯基、1-苄基-3-氮杂环丁烷基、1-二苯基甲基-3-氮杂环丁烷基、1-苄基-3-吡咯烷基或1-苄基-3-哌啶基,最优选为1-二苯基甲基-3-氮杂环丁烷基。
R3优选为2-氯代苯基、2,3-二氯代苯基、2-硝基苯基、3-硝基苯基或2,3-亚甲基二氧基苯基,更优选为3-硝基苯基。
R4优选为甲氧基羰基、乙氧基羰基、2-甲氧基乙氧基羰基、异丙氧基羰基或5,5-二甲基-1,3,2-膦杂环己烷-2-基,更优选为甲氧基羰基或异丙氧基羰基,最优选为异丙氧基羰基。
钙阻滞剂(I)优选为:
(1)R1为甲基、氨基甲酰氧基甲基、2-氨基乙氧基甲基、氨基或氰基的化合物;
(2)R1为甲基或氨基的化合物;
(3)R1为氨基的化合物;
(4)R2为甲基、乙酰基甲基、2-四氢呋喃基甲基、乙基、2-乙酰基乙基、2-(N-甲基-N-苄基氨基)乙基、2-[N-甲基-N-(4-氟代苯基甲基)氨基]乙基、2-(N-苯基-N-苄基氨基)乙基、2-[N-(4-氟代苯基)-N-苄基氨基]乙基、2-[N-(4-氟代苯基)-N-(4-氟代苯基甲基)氨基]乙基、2-(4-苄基-1-哌嗪基)乙基、2-[4-(4-氟代苯基甲基)-1-哌嗪基]乙基、2-(4-二苯基甲基-1-哌嗪基)乙基、2-[4-(二-4-氟代苯基甲基)-1-哌嗪基]乙基、异丙基、异丁基、3-苯基-2-丙烯基、3-(4-氟代苯基)-2-丙烯基、4-苯基-3-丁烯基、2-甲基-3-苯基-2-丙烯基、1-苄基-3-氮杂环丁烷基、1-二苯基甲基-3-氮杂环丁烷基、1-(二-4-氟代苯基甲基)-3-氮杂环丁烷基、1-苄基-3-吡咯烷基、1-(4-氟代苯基甲基)-3-吡咯烷基、1-二苯基甲基-3-吡咯烷基、1-苄基-3-哌啶基、1-(4-氟代苯基甲基)-3-哌啶基或1-二苯基甲基-3-哌啶基的化合物;
(5)R2为甲基、乙酰基甲基、2-四氢呋喃基甲基、乙基、2-(N-甲基-N-苄基氨基)乙基、2-[N-甲基-N-(4-氟代苯基甲基)氨基]乙基、2-(N-苯基-N-苄基氨基)乙基、2-(4-二苯基甲基-1-哌嗪基)乙基、异丙基、异丁基、3-苯基-2-丙烯基、1-苄基-3-氮杂环丁烷基、1-二苯基甲基-3-氮杂环丁烷基、1-(二-4-氟代苯基甲基)-3-氮杂环丁烷基、1-苄基-3-吡咯烷基或1-苄基-3-哌啶基的化合物;
(6)R2为甲基、乙基、2-(4-二苯基甲基-1-哌嗪基)乙基、异丁基、3-苯基-2-丙烯基、1-苄基-3-氮杂环丁烷基、1-二苯基甲基-3-氮杂环丁烷基、1-苄基-3-吡咯烷基或1-苄基-3-哌啶基的化合物;
(7)R2为1-二苯基甲基-3-氮杂环丁烷基的化合物;
(8)R3为2-氯代苯基、2,3-二氯代苯基、2-硝基苯基、3-硝基苯基或2,3-亚甲基二氧基苯基的化合物;
(9)R3为3-硝基苯基的化合物;
(10)R4为甲氧基羰基、乙氧基羰基、2-甲氧基乙氧基羰基、异丙氧基羰基或5,5-二甲基-1,3,2-膦杂环己烷-2-基的化合物;
(11)R4为甲氧基羰基或异丙氧基羰基的化合物;
(12)R4为异丙氧基羰基的化合物;
(13)R5为甲基或乙基的化合物;以及
(14)R5为甲基的化合物。
代表性的钙阻滞剂(I)为美国专利第4,572,909号、美国专利第4,446,325号、美国专利第4,772,596号、美国专利第4,220,649号、美国专利第4,501,748号、美国专利第4,672,068号、美国专利第4,885,284号、美国专利第4,952,592号、美国专利第4,264,611号、特表昭60-500255号、特开昭59-152373号、美国专利第4,892,875号、美国专利第3,985,758号、美国专利第3,485,847号、美国专利第4,338,322号、美国专利第4,154,839号、美国专利第3,799,934号、特开昭60-120861号等中所记载的氨氯地平、阿雷地平、阿折地平、巴尼地平、贝尼地平、西尼地平、依福地平、依高地平、非洛地平、呋尼地平、来米地平、马尼地平、尼卡地平、硝苯地平、尼伐地平、尼索地平、尼群地平或普拉地平,优选氨氯地平、阿折地平、巴尼地平、贝尼地平、西尼地平、非洛地平、来米地平、马尼地平、尼卡地平、硝苯地平、尼伐地平、尼索地平、尼群地平或普拉地平,更优选氨氯地平、阿折地平、巴尼地平、贝尼地平、马尼地平、尼卡地平、尼索地平、尼群地平或普拉地平,更加优选阿折地平、巴尼地平、贝尼地平、马尼地平或尼卡地平,最优选阿折地平。
以下所示为具代表性的钙阻滞剂(I)的平面结构式。
氨氯地平 阿雷地平
阿折地平 巴尼地平
贝尼地平 西尼地平
依福地平 依高地平
非洛地平 呋尼地平
来米地平 马尼地平
尼卡地平 硝苯地平
尼伐地平 尼索地平
尼群地平 普拉地平
氨氯地平记载在美国专利第4,572,909号、特开昭58-167569号等中,其化学名为2-(2-氨基乙氧基甲基基)-(2-氯代苯基)-3-乙氧基羰基-5-甲氧基羰基-6-甲基-1,4-二氢吡啶。
阿雷地平记载在美国专利第4,446,325号等中,其化学名为3-(2-氧代丙氧基羰基)-2,6-二甲基-5-甲氧基羰基-4-(2-硝基苯基)-1,4-二氢吡啶。
阿折地平记载在美国专利第4,772,596号、特开昭63-253082号等中,其化学名为2-氨基-3-(1-二苯基甲基-3-氮杂环丁烷基氧基羰基)-5-异丙氧基羰基-6-甲基-4-(3-硝基苯基)-1,4-二氢吡啶。
巴尼地平记载在美国专利第4,220,649号、特开昭55-301号等中,其化学名为3-(1-苄基-3-吡咯烷氧基羰基)-2,6-二甲基-5-甲氧基羰基-4-(3-硝基苯基)-1,4-二氢吡啶。
贝尼地平记载在美国专利第4,501,748号、特开昭59-70667号等中,其化学名为3-(1-苄基-3-哌啶基氧基羰基)-2,6-二甲基-5-甲氧基羰基-4-(3-硝基苯基)-1,4-二氢吡啶。
西尼地平记载在美国专利第4,672,068号、特开昭60-233058号等中,其化学名为2,6-二甲基-5-(2-甲氧基乙氧基羰基)-4-(3-硝基苯基)-3-(3-苯基-2-丙烯基氧基羰基)-1,4-二氢吡啶。
依福地平记载在美国专利第4,885,284号、特开昭60-69089号等中,其化学名为3-[2-(N-苄基-N-苯基氨基)乙氧基羰基]-2,6-二甲基-5-(5,5-二甲基-1,3,2-二氧杂-2-膦酰基)-4-(3-硝基苯基)-1,4-二氢吡啶。
依高地平记载在美国专利第4,952,592号、特开平1-294675号等中,其化学名为2,6-二甲基-5-异丙氧基羰基-4-(2,3-亚甲基二氧基苯基)-3-[2-[N-甲基-N-(4-氟代苯基甲基)氨基]乙氧基羰基]-1,4-二氢吡啶。
非洛地平记载在美国专利第4,264,611号、特开昭55-9083号等中,其化学名为3-乙氧基羰基-4-(2,3-二氯苯基)-2,6-二甲基-5-甲氧基羰基-1,4-二氢吡啶。
呋尼地平记载在美国专利第4,656,181号、特表昭60-500255号等中,其化学名为2,6-二甲基-5-甲氧基羰基-4-(2-硝基苯基)-3-(2-四氢呋喃基甲氧基羰基)-1,4-二氢吡啶。
来米地平记载在特开昭59-152373号等中,其化学名为2-氨基甲酰氧基甲基-4-(2,3-二氯苯基)-3-异丙氧基羰基-5-甲氧基羰基-6-甲基-1,4-二氢吡啶。
马尼地平记载在美国专利第4,892,875号、特开昭58-201765号等中,其化学名为2,6-二甲基-3-[2-(4-二苯基甲基-1-哌嗪基)乙氧基羰基]-5-甲氧基羰基-4-(3-硝基苯基)-1,4-二氢吡啶。
尼卡地平记载在美国专利第3,985,758号、特开昭49-108082号等中,其化学名为2,6-二甲基-3-[2-(N-苄基-N-甲基氨基)乙氧基羰基]-5-甲氧基羰基-4-(3-硝基苯基)-1,4-二氢吡啶。
硝苯地平记载在美国专利第3,485,847号等中,其化学名为2,6-二甲基-3,5-二甲氧基羰基-4-(2-硝基苯基)-1,4-二氢吡啶。
尼伐地平记载在美国专利第4,338,322号、特开昭52-5777号等中,其化学名为2-氰基-5-异丙氧基羰基-3-甲氧基羰基-6-甲基-4-(3-硝基苯基)-1,4-二氢吡啶。
尼索地平记载在美国专利第4,154,839号、特开昭52-59161号等中,其化学名为2,6-二甲基-3-异丁氧基羰基-5-甲氧基羰基-4-(3-硝基苯基)-1,4-二氢吡啶。
尼群地平记载在美国专利第3,799,934号、特公昭55-27054号等中,其化学名为3-乙氧基羰基-2,6-二甲基-5-甲氧基羰基-4-(3-硝基苯基)-1,4-二氢吡啶。
普拉地平记载在美国专利第5,034,395号、特开昭60-120861号等中,其化学名为2,6-二甲基-5-甲氧基羰基-4-(3-硝基苯基)-3-(3-苯基-2-丙烯-1-基氧基羰基)-1,4-二氢吡啶。
钙阻滞剂(I)存在基于不对称碳原子的光学异构体或者基于双键或环结构的几何异构体,本发明的钙阻滞剂(I)包括所述各种异构体及它们的混合物。
钙阻滞剂(I)的药理学上可接受的盐为酸加成盐,例如可以是氢氟酸盐、盐酸盐、氢溴酸盐、氢碘酸盐之类的氢卤酸盐;硝酸盐;高氯酸盐;硫酸盐;磷酸盐、碳酸盐;甲磺酸盐、三氟甲磺酸盐、乙磺酸盐、五氟乙磺酸盐、丙磺酸盐、丁磺酸盐、戊磺酸盐、己磺酸盐之类可被氟原子取代的碳原子数1-6的烷基磺酸盐;苯磺酸盐、对甲苯磺酸盐之类碳原子数6-10的芳基磺酸盐;乙酸盐、丙酸盐、丁酸盐、苯甲酸盐、富马酸盐、马来酸盐、琥珀酸盐、柠檬酸盐、酒石酸盐、草酸盐、丙二酸盐之类的羧酸盐;或者谷氨酸盐、天冬氨酸盐之类的氨基酸盐等酸加成盐。优选盐酸盐、硫酸盐或羧酸盐,特别优选盐酸盐。
另外,钙阻滞剂(I)或其盐可以作为水合物存在,本发明的钙阻滞剂也包括这些水合物。
本发明的药物组合物中钙阻滞剂(I)的含量通常为0.5-60重量份,优选1-30重量份。
本发明所用的可使药物组合物的水溶液或分散液为至少pH 8的药理学上可接受的碱性介质通常为药学上可接受的碱性无机盐,可以是水溶性的、几乎不溶于水的或实质上不溶于水的物质,例如可以是氢氧化锂、氢氧化钠、氢氧化钾之类的碱金属氢氧化物;氢氧化镁、氢氧化钙、氢氧化钡之类的碱土金属氢氧化物;氢氧化铝;碳酸锂、碳酸钠、碳酸钾之类的碱金属碳酸盐;碳酸镁、碳酸钙、碳酸钡之类的碱土金属碳酸盐;碳酸氢锂、碳酸氢钠、碳酸氢钾之类的碱金属碳酸氢盐;磷酸二钠、磷酸二钾之类的磷酸二碱金属盐;磷酸二镁、磷酸二钙、磷酸二钡之类的磷酸二碱土金属盐;磷酸三钠、磷酸三钾之类的磷酸三碱金属盐;氧化镁、氧化钙之类的碱土金属氧化物;氧化铝;硅酸钠、硅酸钾之类的碱金属硅酸盐;硅酸镁、硅酸钙之类的碱土金属硅酸盐;硅酸-氧化铝之类的复合硅酸-铝化合物;硅酸铝镁(magnesium aluminosilicate)、硅酸铝镁(magnesiumaluminometasilicate)之类的复合铝-镁化合物;或者它们的混合物。优选是碱金属碳酸盐、碱土金属碳酸盐、碱金属碳酸氢盐、碱土金属氧化物、碱金属硅酸盐、碱土金属硅酸盐、复合铝-镁化合物或者它们的混合物;更优选是碳酸钠、碳酸镁、碳酸钙、碳酸氢钠、氧化镁、氧化钙、硅酸镁、硅酸钙、硅酸铝镁(magnesium aluminosilicate)、硅酸铝镁(magnesium aluminometasilicate)或者它们的混合物;最优选是碳酸钠、碳酸氢钠、硅酸钙、硅酸铝镁(magnesium aluminosilicate)、硅酸铝镁(magnesium aluminometasilicate)或者它们的混合物(特别是碳酸钠和硅酸铝镁(magnesium aluminometasilicate)的混合物或者碳酸氢钠和硅酸铝镁(magnesium aluminometasilicate)的混合物,优选碳酸钠或碳酸氢钠与硅酸铝镁的比为1/20-1/2)。
只要药理学上可接受的碱性介质的量能使药物组合物的水溶液或分散液为至少pH8即可,对其没有特别限制,优选通常为1-70重量份,优选5-50重量份。
优选本发明药物组合物的水溶液或分散液的pH为8-12,更优选为9-11,该pH是通过取10倍的药物组合物的单位剂量(例如,片剂的情况下为1片,胶囊剂的情况下为1粒胶囊),向其中加入100ml日本药典规定的精制水,使之溶解或分散,离心分离,之后过滤上清液,用pH仪测定所得溶液的pH而确定的。
另外,在药物组合物吸附了水或者向药物组合物中添加了少量水的时候,作为本发明组分的药理学上可接受的碱性介质可以使药物组合物颗粒的周围形成至少为8的“微-pH”。
本发明的药物组合物可以包含适当的药学上可接受的添加剂,这些添加剂可以是例如赋形剂(例如乳糖、白糖、葡萄糖、甘露糖醇、山梨糖醇之类的糖衍生物;玉米淀粉、马铃薯淀粉、α化淀粉、糊精、羧甲基淀粉和羧甲基淀粉钠之类的淀粉衍生物;预胶化淀粉;结晶纤维素、甲基纤维素、羟丙基纤维素、低取代羟丙基纤维素、羟丙基甲基纤维素、羧甲基纤维素、羧甲基纤维素钙、内交联羧甲基纤维素、内交联羧甲基纤维素钠之类的纤维素衍生物;***胶;葡聚糖;支链淀粉(pullulan);轻质硅酸酐、硅酸水合物、合成硅酸铝、硅酸铝镁(magnesium aluminometasilicate)之类的硅酸盐衍生物;磷酸二钙之类的磷酸盐衍生物;氯化钠之类的氯化物盐衍生物;碳酸钙之类的碳酸盐衍生物;硫酸钙之类的硫酸盐衍生物;或者它们的混合物。优选糖衍生物、纤维素衍生物或它们的混合物,更优选甘露糖醇、结晶纤维素或它们的混合物)、粘合剂(例如上述赋形剂中所例举的化合物;明胶;聚乙烯吡咯烷酮;聚乙二醇;或它们的混合物,优选纤维素衍生物或它们的混合物,更优选羟丙基甲基纤维素)、崩解剂(例如上述赋形剂中所例举的化合物;交联聚乙烯吡咯烷酮;或它们的混合物,优选纤维素衍生物或它们的混合物,更优选低取代羟丙基甲基纤维素、羧甲基纤维素钙或它们的混合物)、润滑剂(例如硬脂酸;硬脂酸钙、硬脂酸镁之类的硬脂酸金属盐;苯甲酸钠之类的苯甲酸金属盐;蜂蜡、鲸蜡之类的蜡;硼酸;二元醇;富马酸、己二酸之类的羧酸类;硫酸钠之类的硫酸金属盐;亮氨酸;月桂基硫酸钠、月桂基硫酸镁之类的月桂基硫酸金属盐;上述赋形剂中所例举的硅酸盐衍生物;上述赋形剂中所例举的淀粉衍生物;氢化植物油;巴西棕榈蜡;蔗糖脂肪酸酯;或者它们的混合物,优选硬脂酸金属盐、硅酸盐衍生物或它们的混合物,更优选硬脂酸钙、硬脂酸镁、硅酸酐或它们的混合物)、稳定剂(例如苯甲酸;苯甲酸钠之类的苯甲酸金属盐;对羟基苯甲酸甲酯、对羟基苯甲酸丙酯之类的对羟基苯甲酸酯类;氯丁醇、苄醇、苯乙醇之类的醇类;苯扎氯胺;苯酚、甲酚之类的酚类;硫柳汞;乙酸酐;山梨酸;或它们的混合物,优选苯甲酸金属盐、对羟基苯甲酸酯或它们的混合物,更优选苯甲酸钠、对羟基苯甲酸甲酯、对羟基苯甲酸丙酯或它们的混合物)、流化剂(例如上述赋形剂中所例举的硅酸盐衍生物;滑石;或它们的混合物,优选轻质硅酸酐、滑石或它们的混合物)、表面活性剂(例如聚山梨醇酯80之类的聚山梨醇酯类;聚氧乙烯硬化蓖麻油60之类的聚氧乙烯硬化蓖麻油类;脱水山梨醇脂肪酸酯类;蔗糖脂肪酸酯类;聚氧乙烯聚氧丙二醇类;聚氧乙烯脂肪酸醚类;硬脂酸聚烃氧基酯类;或它们的混合物,优选聚山梨醇酯80、聚氧乙烯硬化蓖麻油60或它们的混合物)、着色剂、抗氧化剂、矫味矫臭剂(例如通常所用的甜味料、酸味料、香料等)或稀释剂,所用添加剂的种类和量根据片剂、胶囊剂或其它剂型不同而不同,可根据制药领域众所周知的技术进行选择。例如,在片剂的情况下,总药物组合物中粘合剂的含量通常为1-10重量份(优选3-5重量份),崩解剂的含量通常为1-40重量份(优选5-30重量份),润滑剂的含量通常为0.1-10重量份(优选0.5-3重量份),流化剂的含量通常为1-10重量份(优选2-5重量份)。
作为本发明有效组分的钙阻滞剂(I)是公知的,或者是可以通过公知的方法(例如美国专利第4,572,909号、美国专利第4,446,325号、美国专利第4,772,596号、特开昭63-253082号、美国专利第4,220,649号、美国专利第4,501,748号、美国专利第4,672,068号、美国专利第4,885,284号、美国专利第4,952,592号、美国专利第4,264,611号、特表昭60-500255号、特开昭59-152373号、美国专利第4,892,875号、美国专利第3,985,758号、美国专利第3,485,847号、美国专利第4,338,322号、美国专利第4,154,839号、美国专利第3,799,934号、特开昭60-120861号等)容易地进行制备的。
本发明的药物组合物可以采用钙阻滞剂(I)或其盐、碱性介质以及药学上可接受的添加剂,通过众所周知的方法(例如用水进行捏和的方法、湿式制粒方法等)容易地制备。例如,可以根据需要向碱性介质中加入表面活性剂,再加入钙阻滞剂(I)或其盐、赋形剂、粘合剂、崩解剂以及根据需要的其它种类碱性介质等,通过高速搅拌制粒机进行混合,向所得混合物中加入粘合剂的水溶液进行捏和,将所得捏和物用流化床干燥器进行干燥,用粉碎制粒机强制干燥后的粒状物通过筛网,加入润滑剂,用V型混合机使之混合,将所得混合物压片,或者通过装入胶囊分别制成片剂或胶囊剂。或者,可以通过上述高速搅拌制粒机进行混合,加入粘合剂的水溶液进行捏和,将所得捏和物用挤出制粒机制成颗粒,之后通过栅式干燥机进行干燥,用粉碎制粒机强制干燥后的颗粒物通过筛网来制造颗粒剂。
下面给出实施例以对本发明进行更详细的说明,但是本发明并不限于这些实施例。
实施发明的最佳方式
(实施例1)片剂1
用下表1的处方所示成分和用量制造标记片剂。在高速搅拌制粒机中边搅拌,边向轻质硅酸铝镁(magnesium aluminometasilicate)(等级FL2)中加入聚山梨醇酯80,再加入阿折地平、结晶纤维素、D-甘露糖醇、低取代羟丙基纤维素和碳酸氢钠,之后通过高速搅拌制粒机进行混合。向该混合物中加入羟丙基纤维素水溶液进行捏和,通过进风温度90℃的流化床干燥器将所得捏和物干燥至排风温度为55℃。通过粉碎制粒机强制干燥后的粒状物通过1.0mm的筛网,接着向其中加入硬脂酸镁,用V型混合机混合10分钟。用直径8.0mm的冲头将所得混合物成形。另外,在实施例1-5和参考实施例1中,使用了8mg阿折地平。
(表1)
将该制剂用玛瑙研钵混合,用20目的筛网进行筛分,取1000mg(5片份)所得粉末,加入50ml日本药典规定的精制水,振荡20分钟,以3000rpm离心分离10分钟,使上清液通过0.45μm过滤器,用pH仪测定所得溶液的pH。显示出所得溶液的pH为9.5。
该制剂在避光且耐水环境中、25℃下储存36个月后,仍有98%未变化。
(实施例2)片剂2
用下表2的处方所示成分和用量制造标记片剂。将轻质硅酸铝镁(magnesium aluminometasilicate)(等级FL2)和轻质硅酸酐在高速搅拌制粒机中混合,加入聚山梨醇酯80,再加入阿折地平、结晶纤维素、D-甘露糖醇、低取代羟丙基纤维素、羧甲基纤维素钙(carmellosecalcium)和碳酸氢钠,之后通过高速搅拌制粒机进行混合。向该混合物中加入羟丙基纤维素水溶液进行捏和,通过进风温度90℃的流化床干燥器将所得捏和物干燥至排风温度为55℃。通过粉碎制粒机强制干燥后的粒状物通过1.0mm的筛网,接着向其中加入硬脂酸镁,用V型混合机混合10分钟。用直径8.0mm的冲头将所得混合物成形。
(表2)
通过与实施例1同样的方法测定该制剂的pH。显示出所得溶液的pH为10.0。
该制剂在避光且耐水环境中、25℃下储存36个月后,仍有99%来变化。
(实施例3)胶囊剂1
用表2的处方所示成分和用量,通过与实施例2同样的方法配制混合物,填充到3号胶囊中,制成标记制剂。
通过与实施例1同样的方法测定该制剂的pH。显示出所得溶液的pH为10.0。
该制剂在避光且耐水环境中、25℃下储存36个月后,仍有98%未变化。
(实施例4)片剂3
除用碳酸钠代替表2处方中的碳酸氢钠外,与实施例2同样操作,制备标记片剂。
通过与实施例1同样的方法测定该制剂的pH。显示出所得溶液的pH为11.0。
该制剂在避光且耐水环境中、25℃下储存36个月后,仍有95%未变化。
(实施例5)片剂4
用下表3的处方所示成分和用量制造标记片剂。在高速搅拌制粒机中边搅拌,边向硅酸钙中加入聚山梨醇酯80,再加入阿折地平、D-甘露糖醇和低取代羟丙基纤维素,之后通过高速搅拌制粒机进行混合。向该混合物中加入羟丙基纤维素水溶液进行捏和,通过进风温度90℃的流化床干燥器将所得捏和物干燥至排风温度为55℃。通过粉碎制粒机强制干燥后的粒状物通过1.0mm的筛网,接着向其中加入硬脂酸镁,用V型混合机混合10分钟。用直径8.0mm的冲头将所得混合物成形。
(表3)
用与实施例1同样的方法测定该制剂的pH。显示出所得溶液的pH为9.3。
该制剂在避光且耐水环境中、25℃下储存36个月后,仍有97%未变化。
(比较例1)片剂A
用下表4的处方所示成分和用量制造标记片剂。加入阿折地平、D-甘露糖醇和低取代羟丙基纤维素,之后通过高速搅拌制粒机边搅拌,边加入聚山梨醇酯80。向该混合物中加入羟丙基纤维素水溶液进行捏和,通过进风温度90℃的流化床干燥器将所得捏和物干燥至排风温度为55℃。通过粉碎制粒机强制干燥后的粒状物通过1.0mm的筛网,接着向其中加入硬脂酸镁,用V型混合机混合10分钟。用直径8.0mm的冲头将所得混合物成形。
(表4)
用与实施例1同样的方法测定该制剂的pH。显示出所得溶液的pH为7.4。
该制剂在避光且耐水环境中、25℃下储存36个月后,仍有70%未变化。
产业上的可利用性
本发明的药物组合物是具有优良的储存稳定性、而且显示出快速肠道吸收性、通过简便的湿式制粒法制备的组合物,是作为药物制剂极为有用的药物组合物。
Claims (18)
2.权利要求1的药物组合物,其中R2为1-苄基-3-氮杂环丁烷基、1-二苯基甲基-3-氮杂环丁烷基或1-(二-4-氟代苯基甲基)-3-氮杂环丁烷基。
3.权利要求1的药物组合物,其中R2为1-苄基-3-氮杂环丁烷基或1-二苯基甲基-3-氮杂环丁烷基。
4.权利要求1的药物组合物,其中R2为1-二苯基甲基-3-氮杂环丁烷基。
5.权利要求1-4中任一项的药物组合物,其中R3为2-硝基苯基或3-硝基苯基。
6.权利要求1-4中任一项的药物组合物,其中R3为3-硝基苯基。
7.权利要求1-4中任一项的药物组合物,其中R4为甲氧羰基、乙氧羰基或异丙氧羰基。
8.权利要求1-4中任一项的药物组合物,其中R4为甲氧羰基或异丙氧羰基。
9.权利要求1-4中任一项的药物组合物,其中R4为异丙氧羰基。
10.权利要求1-4中任一项的药物组合物,其中R5为甲基或乙基。
11.权利要求1-4中任一项的药物组合物,其中R5为甲基。
12.权利要求1的药物组合物,其中钙阻滞剂(I)为阿折地平。
13.权利要求1-4中任一项的药物组合物,其中碱性介质为碱金属硅酸盐、碱土金属硅酸盐、复合铝-镁化合物或者它们的混合物。
14.权利要求1-4中任一项的药物组合物,其中碱性介质为硅酸镁、硅酸钙、magnesium aluminosilicate、magnesium alumino-metasilicate或者它们的混合物。
15.权利要求1-4中任一项的药物组合物,其中碱性介质为硅酸钙、magnesium aluminosilicate、magnesium aluminometasilicate或者它们的混合物。
16.权利要求1-4中任一项的药物组合物,其中碱性介质为碳酸钠和magnesium aluminometasilicate的混合物或者碳酸氢钠和magnesium aluminometasilicate的混合物。
17.权利要求1-4中任一项的药物组合物,该药物组合物的水溶液或分散液的pH为8-12。
18.权利要求1-4中任一项的药物组合物,该药物组合物的水溶液或分散液的pH为9-11。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP108850/2000 | 2000-04-11 | ||
JP108850/00 | 2000-04-11 | ||
JP2000108850 | 2000-04-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1436077A CN1436077A (zh) | 2003-08-13 |
CN100450483C true CN100450483C (zh) | 2009-01-14 |
Family
ID=18621626
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB018109438A Expired - Fee Related CN100450483C (zh) | 2000-04-11 | 2001-04-10 | 含有钙阻滞剂的稳定药物组合物 |
Country Status (23)
Country | Link |
---|---|
US (4) | US20030073670A1 (zh) |
EP (1) | EP1285655B1 (zh) |
JP (1) | JP2009143923A (zh) |
KR (1) | KR100756565B1 (zh) |
CN (1) | CN100450483C (zh) |
AT (1) | ATE363281T1 (zh) |
AU (2) | AU2001246883B2 (zh) |
BR (1) | BR0109991A (zh) |
CA (1) | CA2405046C (zh) |
CZ (1) | CZ301790B6 (zh) |
DE (1) | DE60128683T2 (zh) |
ES (1) | ES2287110T3 (zh) |
HK (1) | HK1050324A1 (zh) |
HU (1) | HUP0300444A3 (zh) |
IL (2) | IL152021A0 (zh) |
MX (1) | MXPA02010040A (zh) |
NO (1) | NO329943B1 (zh) |
NZ (1) | NZ521853A (zh) |
PL (1) | PL201513B1 (zh) |
RU (1) | RU2239432C2 (zh) |
TW (1) | TWI246921B (zh) |
WO (1) | WO2001076598A1 (zh) |
ZA (1) | ZA200207933B (zh) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3595765B2 (ja) * | 2000-09-27 | 2004-12-02 | 信越化学工業株式会社 | 低置換度ヒドロキシプロピルセルロースを含む乾式直打用基剤 |
BR0317671A (pt) * | 2002-12-24 | 2005-11-29 | Sankyo Co | Composto |
BRPI0406987A (pt) * | 2003-01-31 | 2006-01-10 | Sankyo Co | Medicamento para a prevenção e/ou tratamento de arteriosclerose, medicamentos para a inibição de proliferação de células do músculo liso vascular, de formação de neoìntima dos vasos sanguìneos e de remodelação vascular, medicamento para a prevenção de restenose que segue intervenção coronária percutânea, e, medicamentos para a profilaxia e/ou tratamento de hipertensão ou doenças causadas por hipertensão ou doenças causadas por hipertensão, de doenças cardìacas, de angina do peito, de infarto miocárdico, de arritmia, de morte súbita, de insuficiência cardìaca, de hipertrofia cardìaca, de doenças renais, de nefropatia diabética, de glomerulonefrite, de nefrosclerose, de doenças cerebrovasculares, de infarto cerebral, e de hemorragia cerebral |
DK1628663T3 (da) | 2003-05-15 | 2010-03-08 | Roskamp Res Llc | Fremgangsmåde til fremstilling af medikamenter til reduktion af amyloid-aflejring, amyloid-neurotoksicitet og mikrogliose |
CN1762354B (zh) * | 2004-10-18 | 2010-07-28 | 上海药明康德新药开发有限公司 | 一种含有钙阻滞剂的稳定药物组合物 |
WO2006133045A1 (en) * | 2005-06-03 | 2006-12-14 | Elan Pharma International, Limited | Nanoparticulate benidipine compositions |
US20100221327A1 (en) * | 2005-06-15 | 2010-09-02 | Elan Pharma International Limited | Nanoparticulate azelnidipine formulations |
KR101384841B1 (ko) * | 2005-06-27 | 2014-04-15 | 다이이찌 산쿄 가부시키가이샤 | 안지오텐신 ⅱ 수용체 길항제 및 칼슘 채널 차단제를함유한 약학 제제 |
TW200806648A (en) * | 2005-11-29 | 2008-02-01 | Sankyo Co | Acid addition salts of dihydropyridine derivatives |
TW200736245A (en) * | 2005-11-29 | 2007-10-01 | Sankyo Co | Acid addition salts of optically active dihydropyridine derivatives |
CN101103979B (zh) * | 2006-07-14 | 2010-12-08 | 海南盛科生命科学研究院 | 一种阿折地平药物组合物及其制备方法 |
TWI399223B (zh) * | 2006-09-15 | 2013-06-21 | Daiichi Sankyo Co Ltd | 奧美沙坦酯及氨氯地平之固體劑型 |
GB0709541D0 (en) * | 2007-05-17 | 2007-06-27 | Jagotec Ag | Pharmaceutical excipient |
JP2008290989A (ja) * | 2007-05-28 | 2008-12-04 | Ube Ind Ltd | ジヒドロピリジン誘導体の酸付加塩を含有する医薬 |
CN101883564B (zh) | 2007-10-05 | 2013-10-16 | 阿尔茨海默病学会美国公司 | 使用(-)-尼伐地平对映体减少淀粉状蛋白沉积、淀粉状蛋白神经毒性和小神经胶质增生的方法 |
EP2307022A4 (en) * | 2007-10-31 | 2011-08-24 | Equitech Corp | ENHANCED NON-STEROID ANTI-INFLAMMATORY FORMULATIONS (NSAIDs) |
EP2403482B1 (en) | 2009-03-04 | 2017-12-27 | Emplicure AB | Abuse resistant formulation |
ES2673196T3 (es) | 2009-05-08 | 2018-06-20 | Emplicure Ab | Composición para la administración sostenida de fármacos que comprende aglutinante geopolimérico |
NO2613784T3 (zh) | 2010-09-07 | 2018-05-12 | ||
JP5917034B2 (ja) * | 2011-07-15 | 2016-05-11 | ニプロ株式会社 | カルシウムブロッカーを含有する固形医薬組成物 |
US8679547B2 (en) * | 2011-10-20 | 2014-03-25 | Tomita Pharmaceutical Co., Ltd. | Method for manufacturing calcium silicate based composition |
CN102921008B (zh) * | 2012-11-16 | 2014-01-01 | 南京正大天晴制药有限公司 | 一种含有钙阻滞剂的药物组合物 |
CN104473888B (zh) * | 2014-11-20 | 2017-01-18 | 南京正大天晴制药有限公司 | 一种阿折地平的药物组合物 |
JP6426115B2 (ja) * | 2016-04-06 | 2018-11-21 | ニプロ株式会社 | カルシウムブロッカーを含有する固形医薬組成物 |
JP6462625B2 (ja) * | 2016-04-06 | 2019-01-30 | ニプロ株式会社 | カルシウムブロッカーを含有する錠剤 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0521310A2 (en) * | 1991-06-05 | 1993-01-07 | FUJIREBIO Inc. | Solid dispersion tablets containing 1,4-dihydropyridine derivatives and process for the preparation thereof |
JPH10167966A (ja) * | 1996-12-03 | 1998-06-23 | Nippon Chemiphar Co Ltd | 経口持続性製剤 |
EP0884054A2 (en) * | 1997-05-13 | 1998-12-16 | Vita-Invest, S.A. | Fixed-dose association of an angiotensin-converting enzyme inhibitor and of a calcium channel antagonist for the treatment of cardiovascular illnesses |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1670827C3 (de) * | 1967-03-20 | 1974-10-24 | Bayer Ag, 5090 Leverkusen | 4-(2'-Nitrophenyl)-2,6-dimethyl-3,5-dicarbmethoxy-1,4-dihydropyridin |
DE2117571C3 (de) * | 1971-04-10 | 1979-10-11 | Bayer Ag, 5090 Leverkusen | Unsymmetrische 1,4-Dihydropyridin-33-dicarbonsäureester, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel |
US3985758A (en) * | 1973-02-20 | 1976-10-12 | Yamanouchi Pharmaceutical Co., Ltd. | 1,4-Dihydropyridine derivatives |
US4338322A (en) * | 1975-07-02 | 1982-07-06 | Fujisawa Pharmaceutical Co., Ltd. | 1,4-Dihydropyridine derivatives, pharmaceutical compositions containing same and methods of effecting vasodilation using same |
US4154839A (en) * | 1975-11-05 | 1979-05-15 | Bayer Aktiengesellschaft | 2,6-Dimethyl-3-carboxymethoxy-4-(2-nitrophenyl)-5-carbisobutoxy-1,4-dihydropyridine |
JPS55301A (en) * | 1978-02-14 | 1980-01-05 | Yamanouchi Pharmaceut Co Ltd | 1,4-dihydropyridine-3,5-dicarboxylic ester derivative and its preparation |
SE429652B (sv) * | 1978-06-30 | 1983-09-19 | Haessle Ab | 2.6-dimetyl-4-(2.3-diklorfenyl)-1.4-dihydropyridin-3.5-dikarboxylsyra-3-metylester-5-etylester |
GB2111978B (en) * | 1981-10-19 | 1985-05-01 | Maruko Pharmaceutical Co | 1 4-dihydropyridine compounds |
DK161312C (da) * | 1982-03-11 | 1991-12-09 | Pfizer | Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden |
WO1983003249A1 (en) * | 1982-03-17 | 1983-09-29 | Yoshitomi Pharmaceutical | 1,4-dihydropyridine-3,5-dicarboxylate derivatives |
EP0094159B1 (en) * | 1982-05-10 | 1990-03-14 | Takeda Chemical Industries, Ltd. | Dihydropyridine derivatives, their production and use |
JPS59225162A (ja) * | 1983-06-03 | 1984-12-18 | Kyowa Hakko Kogyo Co Ltd | 1,4−ジヒドロピリジン誘導体 |
US4656181A (en) * | 1982-11-24 | 1987-04-07 | Cermol S.A. | Esters of 1,4-dihydropyridines, processes for the preparation of the new esters, and medicaments containing the same |
JPS59101423A (ja) * | 1982-12-02 | 1984-06-12 | Takada Seiyaku Kk | 新規なニフエジピン固形製剤 |
US4520112A (en) * | 1983-03-09 | 1985-05-28 | The Johns Hopkins University | Assay method for organic calcium antagonist drugs and a kit for such an assay |
JPS60120861A (ja) * | 1983-12-02 | 1985-06-28 | Otsuka Pharmaceut Co Ltd | ジヒドロピリジン誘導体 |
US4672068A (en) * | 1984-05-04 | 1987-06-09 | Fujirebio Kabushiki Kaisha | Antihypertensive 1,4-dihydropyridines having a conjugated ester |
US4794111A (en) * | 1984-05-23 | 1988-12-27 | Bayer Aktiengesellschaft | Dihydropyridine preparations containing β-blockers |
FI853478L (fi) * | 1984-09-14 | 1986-03-15 | Ciba Geigy Ag | Foerfarande foer framstaellning av fenylalkylfoereningar. |
US4762950A (en) * | 1985-12-16 | 1988-08-09 | Basf Corporation | Selective oxyalkylaton of N-(2-hydroxyalkyl)-aniline |
US4885284A (en) * | 1986-01-22 | 1989-12-05 | Nissan Chemical Industries Ltd. | Dihydropyridine-5-phosphonic acid cyclic propylene ester |
US4940556A (en) * | 1986-01-30 | 1990-07-10 | Syntex (U.S.A.) Inc. | Method of preparing long acting formulation |
US5198226A (en) * | 1986-01-30 | 1993-03-30 | Syntex (U.S.A.) Inc. | Long acting nicardipine hydrochloride formulation |
SE8601624D0 (sv) | 1986-04-11 | 1986-04-11 | Haessle Ab | New pharmaceutical preparations |
US4772596A (en) * | 1986-10-09 | 1988-09-20 | Sankyo Company Limited | Dihydropyridine derivatives, their preparation and their use |
JPS6396126A (ja) * | 1986-10-13 | 1988-04-27 | Taisho Pharmaceut Co Ltd | 安定化組成物 |
EP0302980B1 (fr) * | 1987-08-03 | 1991-03-13 | Laboratorios Delagrange S.A. | 1,4-Dihydropyridines, leur procédé de préparation et leur application comme médicaments |
SE8703881D0 (sv) * | 1987-10-08 | 1987-10-08 | Haessle Ab | New pharmaceutical preparation |
SU1722252A3 (ru) * | 1988-06-15 | 1992-03-23 | Сименс Аг (Фирма) | Устройство дл вихретокового контрол труб теплообменника с трубами U-образной формы |
US5484789A (en) * | 1989-10-31 | 1996-01-16 | The University Of North Carolina At Chapel Hill | Calcium channel blockers to improve preservation of organs stored for transplantation |
US5209933A (en) * | 1990-01-10 | 1993-05-11 | Syntex (U.S.A.) Inc. | Long acting calcium channel blocker composition |
GB2245559A (en) * | 1990-06-25 | 1992-01-08 | Farmos Oy | Bioceramic system for delivery of a bioactive compound. |
US5209993A (en) * | 1990-08-24 | 1993-05-11 | General Motors Corporation | Method of enveloping battery plates |
HU9203780D0 (en) * | 1991-12-12 | 1993-03-29 | Sandoz Ag | Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them |
US5958458A (en) * | 1994-06-15 | 1999-09-28 | Dumex-Alpharma A/S | Pharmaceutical multiple unit particulate formulation in the form of coated cores |
WO1996006829A1 (fr) * | 1994-08-29 | 1996-03-07 | Mercian Corporation | Derive de 1,4-dihydropyrydine |
JP3491506B2 (ja) * | 1997-10-14 | 2004-01-26 | 宇部興産株式会社 | ジヒドロピリジン誘導体の製造法 |
SE9704400D0 (sv) * | 1997-11-28 | 1997-11-28 | Astra Ab | Porous inorganic particles as carriers for drug substances |
US6753011B2 (en) * | 2000-01-14 | 2004-06-22 | Osmotica Corp | Combined diffusion/osmotic pumping drug delivery system |
EA200300409A1 (ru) * | 2000-10-26 | 2003-08-28 | Пфайзер Продактс Инк. | Пиримидин-2,4,6-трионовые ингибиторы металлопротеиназы |
EP1309558A1 (en) * | 2000-12-29 | 2003-05-14 | Synthon Licensing, Ltd. | Aspartate derivative of amlodipine as calcium channel antagonist |
NZ532316A (en) * | 2001-10-24 | 2005-10-28 | Sepracor Inc | Method of resolving amlodipine racemate |
-
2001
- 2001-04-10 CZ CZ20023353A patent/CZ301790B6/cs not_active IP Right Cessation
- 2001-04-10 AU AU2001246883A patent/AU2001246883B2/en not_active Ceased
- 2001-04-10 CA CA002405046A patent/CA2405046C/en not_active Expired - Fee Related
- 2001-04-10 AT AT01919870T patent/ATE363281T1/de not_active IP Right Cessation
- 2001-04-10 PL PL357572A patent/PL201513B1/pl not_active IP Right Cessation
- 2001-04-10 WO PCT/JP2001/003087 patent/WO2001076598A1/ja active IP Right Grant
- 2001-04-10 AU AU4688301A patent/AU4688301A/xx active Pending
- 2001-04-10 KR KR1020027013417A patent/KR100756565B1/ko not_active IP Right Cessation
- 2001-04-10 IL IL15202101A patent/IL152021A0/xx unknown
- 2001-04-10 CN CNB018109438A patent/CN100450483C/zh not_active Expired - Fee Related
- 2001-04-10 BR BR0109991-4A patent/BR0109991A/pt not_active IP Right Cessation
- 2001-04-10 NZ NZ521853A patent/NZ521853A/en not_active IP Right Cessation
- 2001-04-10 HU HU0300444A patent/HUP0300444A3/hu unknown
- 2001-04-10 RU RU2002127125/15A patent/RU2239432C2/ru not_active IP Right Cessation
- 2001-04-10 EP EP01919870A patent/EP1285655B1/en not_active Expired - Lifetime
- 2001-04-10 ES ES01919870T patent/ES2287110T3/es not_active Expired - Lifetime
- 2001-04-10 DE DE60128683T patent/DE60128683T2/de not_active Expired - Lifetime
- 2001-04-10 TW TW090108557A patent/TWI246921B/zh not_active IP Right Cessation
- 2001-04-10 MX MXPA02010040A patent/MXPA02010040A/es active IP Right Grant
-
2002
- 2002-09-30 IL IL152021A patent/IL152021A/en not_active IP Right Cessation
- 2002-10-02 ZA ZA200207933A patent/ZA200207933B/en unknown
- 2002-10-10 US US10/268,308 patent/US20030073670A1/en not_active Abandoned
- 2002-10-10 NO NO20024885A patent/NO329943B1/no not_active IP Right Cessation
-
2003
- 2003-04-09 HK HK03102533A patent/HK1050324A1/xx not_active IP Right Cessation
-
2007
- 2007-02-08 US US11/704,122 patent/US20070142442A1/en not_active Abandoned
-
2008
- 2008-12-16 JP JP2008319561A patent/JP2009143923A/ja active Pending
-
2010
- 2010-02-03 US US12/658,202 patent/US20100144697A1/en not_active Abandoned
- 2010-02-03 US US12/658,201 patent/US20100144696A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0521310A2 (en) * | 1991-06-05 | 1993-01-07 | FUJIREBIO Inc. | Solid dispersion tablets containing 1,4-dihydropyridine derivatives and process for the preparation thereof |
JPH10167966A (ja) * | 1996-12-03 | 1998-06-23 | Nippon Chemiphar Co Ltd | 経口持続性製剤 |
EP0884054A2 (en) * | 1997-05-13 | 1998-12-16 | Vita-Invest, S.A. | Fixed-dose association of an angiotensin-converting enzyme inhibitor and of a calcium channel antagonist for the treatment of cardiovascular illnesses |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100450483C (zh) | 含有钙阻滞剂的稳定药物组合物 | |
JP4509118B2 (ja) | 医薬組成物及びその製造方法、並びに医薬組成物におけるジヒドロピリジン系化合物の安定化方法 | |
US5198226A (en) | Long acting nicardipine hydrochloride formulation | |
US4940556A (en) | Method of preparing long acting formulation | |
JP4977462B2 (ja) | 3−[(2−{[4−(ヘキシルオキシカルボニルアミノ−イミノ−メチル)−フェニルアミノ]−メチル}−1−メチル−1h−ベンズイミダゾール−5−カルボニル)−ピリジン−2−イル−アミノ]−プロピオン酸エチルエステルまたはその塩を含む錠剤 | |
CN101151019B (zh) | N-[5-(氨基磺酰基)-4-甲基-1,3-噻唑-2-基]-n-甲基-2-[4-(2-吡啶基)苯基]乙酰胺的药物制剂 | |
AU2003279803A1 (en) | Stabilized pharmaceutical composition containing basic excipients | |
US20100158959A1 (en) | Stable Combinations of Amlodipine Besylate and Benazepril Hydrochloride | |
BRPI0812442A2 (pt) | formas amorfas estabilizadas de mesilato de imatinib | |
CA2038744C (en) | Pharmaceutical composition containing slightly water-soluble drug | |
JP3110794B2 (ja) | 1,4−ジヒドロピリジン誘導体を含有する製剤 | |
JP4327376B2 (ja) | カルシウムブロッカーを含有する安定化された薬剤組成物 | |
AU2005336956A1 (en) | Stable combinations of amlodipine besylate and benazepril hydrochloride | |
JP5917034B2 (ja) | カルシウムブロッカーを含有する固形医薬組成物 | |
JP7101464B2 (ja) | アジルサルタン又はその塩及びアムロジピン又はその塩含有錠剤の品質向上方法、並びにアジルサルタン又はその塩及びアムロジピン又はその塩含有錠剤及びその製造方法 | |
JP6426115B2 (ja) | カルシウムブロッカーを含有する固形医薬組成物 | |
EP1932528A1 (en) | Stable composition of amlodipine besylate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090114 Termination date: 20130410 |